Sugi Predict

Sugi Predict / Compounds / SCHEMBL349039

SCHEMBL349039

SCHEMBL349039

O=Cc1cc([N+](=O)[O-])ccc1F

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 2/20 0.62
▸ ALDH1A1 P00352 5/20 0.58
▸ HIF1A Q16665 1/20 0.58
▸ PTPN1 P18031 1/20 0.46
▸ LMNA P02545 3/20 0.43
▸ TSHR P16473 2/20 0.43
▸ TDP1 Q9NUW8 3/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ PLG P00747 1/20 0.42
▸ MAPT P10636 2/20 0.42
▸ NTSR1 P30989 1/20 0.42
▸ TXNRD1 Q16881 1/20 0.42
▸ TXNRD3 Q86VQ6 1/20 0.42
▸ TXNRD2 Q9NNW7 1/20 0.42
▸ PTPRC P08575 1/20 0.41
▸ S100A4 P26447 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL7400535 0.96 ERN1 (0.59) ERN1ALDH1A1HIF1APTPN1LMNA
SCHEMBL1591294 0.85 ERN1 (0.58) ERN1ALDH1A1HIF1APTPN1LMNA
SCHEMBL4647893 0.83 ALDH1A1 (0.56) ERN1ALDH1A1HIF1ALMNATSHR
SCHEMBL28750322 0.83 ALDH1A1 (0.56) ERN1ALDH1A1HIF1ALMNATSHR
SCHEMBL16951459 0.83 ALDH1A1 (0.56) ERN1ALDH1A1HIF1ALMNATSHR
SCHEMBL30648783 0.83 ALDH1A1 (0.56) ERN1ALDH1A1HIF1ALMNATSHR
SCHEMBL27720125 0.82 HSPB1 (0.58) ERN1ALDH1A1HIF1AMAPTMEN1
SCHEMBL2652355 0.82 ERN1 (0.69) ERN1ALDH1A1PTPN1LMNATSHR
SCHEMBL2476768 0.80 ALDH1A1 (0.53) ERN1ALDH1A1HIF1ALMNATSHR
SCHEMBL3062921 0.80 ALDH1A1 (0.53) ERN1ALDH1A1HIF1ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118619927-A Methylene hydrazine substituted benzene compound, preparation method and application thereof 四川省医学科学院·四川省人民医院 2024-09-10 — — CN claimed
CN-116396171-B Synthesis method of 2-fluoro-5-nitrobenzaldehyde 南通大学 2023-12-26 — — CN claimed
CN-116396171-A Synthesis method of 2-fluoro-5-nitrobenzaldehyde 南通大学 2023-07-07 — — CN claimed
CN-108997310-B Asymmetric 3-pyridine substituted 3, 5-diarylmethylene-4-piperidone and preparation method thereof 滨州医学院 2023-06-27 — — CN claimed
CN-108997311-B Asymmetric 4-pyridine substituted 3, 5-diarylmethylene-4-piperidone and preparation method thereof 滨州医学院 2023-06-23 — — CN claimed
CN-108997310-A Bis- aryl methylene -4- the piperidones of 3,5- and preparation method thereof that asymmetric 3- pyridine replaces 滨州医学院 2018-12-14 — — CN claimed
CN-108997311-A Bis- aryl methylene -4- the piperidones of 3,5- and preparation method thereof that asymmetric 4- pyridine replaces 滨州医学院 2018-12-14 — — CN claimed
CN-107722039-A A kind of synthesis PNU 286607 and the like method 青岛农业大学 2018-02-23 — — CN claimed
EP-2245132-B1 ENCAPSULATED BENEFIT AGENT UNILEVER PLC NO 41424 (GB) 2017-10-18 — — EP claimed
CN-102015993-B Encapsulated benefit agent UNILEVER PLC 2013-03-27 — — CN claimed
CN-102015993-A Encapsulated benefit agent UNILEVER PLC 2011-04-13 — — CN claimed
EP-2245132-A1 ENCAPSULATED BENEFIT AGENT Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House (GB) 2010-11-03 — — EP claimed
WO-2009103576-A1 ENCAPSULATED BENEFIT AGENT UNILEVER PLC (GB) 2009-08-27 — — WO claimed
US-20060084176-A1 Detection of uronium salts YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-04-20 — — US claimed
EP-1189891-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION Bioscience AG (DE) 2002-03-27 — — EP claimed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 — — US claimed
WO-2001000594-A1 TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2001-01-04 — — WO claimed
US-4456772-A Process for the preparation of optionally substituted fluoro-nitro-benzaldehydes BAYER AKTIENGESELLSCHAFT (DE) 1984-06-26 — — US claimed
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER CANCER RESEARCH TECH LIMITED (GB) 2026-05-21 — — US disclosed
EP-0061113-A1 Method for the preparation of optionally substituted fluoronitrobenzaldehydes BAYER AG (DE) 1982-09-29 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137703-A1 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE AND 7-AMINO-1-PYRIMIDO[4,5-D]PYRIMIDIN-2(1 H)-ONE DERIVATIVES AS EGFR INHIBITORS FOR THE TREATMENT OF CANCER EGFR, KRAS, O60361 ERN1 707/4885ALDH1A1 999/4885HIF1A 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.